Aldeyra Therapeutics (ALDX) said Tuesday that it completed enrollment in a phase 3 trial of 0.25% reproxalap ophthalmic solution for the treatment of...
Aldeyra Therapeutics (ALDX) said Tuesday that a midstage clinical trial of its reproxalap ophthalmic solution in patients with dry eye disease achieved its...
...
...
| Address | 131 Hartwell Avenue Lexington, Massachusetts 02421 |
| Phone | +1.781.761.4904 |
| Number of Employees | 19 |
| Recent SEC Filing | 11/09/2021 8-K |
| President, Chief Executive Officer & Director | Todd C. Brady |
| Chief Financial Officer | Joshua Reed |
| Vice President & Controller | Bruce Greenberg |
| Senior Vice President-Clinical Development | James A. Gow |
| Price Open | $8.25 |
| Previous Close | $7.92 |
| 52 Week Range | $6.47 - 15.95 |
| Market Capitalization | $446.1 M |
| Shares Outstanding | 58.1 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/10/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.06 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -33.38% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
